{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:18:24Z","timestamp":1792293504581,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41591-026-04459-7","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:01:35Z","timestamp":1780336895000},"page":"2888-2897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4063-9813","authenticated-orcid":false,"given":"Zhi","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8604-6311","authenticated-orcid":false,"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2539-7732","authenticated-orcid":false,"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoxing","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9366-2314","authenticated-orcid":false,"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diansheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfeng","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puhan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2922","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongshun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianbao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushuang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangsheng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejun","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"4459_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"4459_CR2","unstructured":"Ferlay J. et al. Global Cancer Observatory: Cancer Today \u2013 All Cancers. Global Cancer Observatory https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/39-all-cancers-fact-sheet.pdf (2024)."},{"key":"4459_CR3","unstructured":"Ferlay J. et al. Global Cancer Observatory: Cancer Today \u2013 Stomach. Global Cancer Observatory https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/7-stomach-fact-sheet.pdf (2024)."},{"key":"4459_CR4","unstructured":"Ferlay J. et al. Global Cancer Observatory: Cancer Today \u2013 Asia. Global Cancer Observatory https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/935-asia-fact-sheet.pdf (2024)."},{"key":"4459_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/JEP.S242958","volume":"12","author":"H El Darsa","year":"2020","unstructured":"El Darsa, H., El Sayed, R. & Abdel-Rahman, O. MET inhibitors for the treatment of gastric cancer: what\u2019s their potential?. J. Exp. Pharmacol. 12, 349\u2013361 (2020).","journal-title":"J. Exp. Pharmacol."},{"key":"4459_CR6","doi-asserted-by":"publisher","first-page":"104616","DOI":"10.1016\/j.ebiom.2023.104616","volume":"92","author":"T Hess","year":"2023","unstructured":"Hess, T. et al. Dissecting the genetic heterogeneity of gastric cancer. EBioMedicine 92, 104616 (2023).","journal-title":"EBioMedicine"},{"key":"4459_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41416-022-02047-3","volume":"128","author":"M Kock Am Brink","year":"2023","unstructured":"Kock Am Brink, M. et al. Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinoma. Br. J. Cancer 128, 375\u2013386 (2023).","journal-title":"Br. J. Cancer"},{"key":"4459_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5230\/jgc.2025.25.e3","volume":"25","author":"HS Lee","year":"2025","unstructured":"Lee, H. S. Spatial and temporal tumor heterogeneity in gastric cancer: discordance of predictive biomarkers. J. Gastric Cancer 25, 192\u2013209 (2025).","journal-title":"J. Gastric Cancer"},{"key":"4459_CR9","doi-asserted-by":"publisher","first-page":"107327482210992","DOI":"10.1177\/10732748221099227","volume":"29","author":"Y Li","year":"2022","unstructured":"Li, Y., Feng, A., Zheng, S., Chen, C. & Lyu, J. Recent estimates and predictions of 5-year survival in patients with gastric cancer: a model-based period analysis. Cancer Control 29, 10732748221099227 (2022).","journal-title":"Cancer Control"},{"key":"4459_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick, F. et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1005\u20131020 (2022).","journal-title":"Ann. Oncol."},{"key":"4459_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"FH Wang","year":"2024","unstructured":"Wang, F. H. et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 44, 127\u2013172 (2024).","journal-title":"Cancer Commun."},{"key":"4459_CR12","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655\u20131668 (2023).","journal-title":"Lancet"},{"key":"4459_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N. Engl. J. Med. 393, 336\u2013348 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4459_CR14","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li, J. et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol. 34, 1448\u20131454 (2016).","journal-title":"J. Clin. Oncol."},{"key":"4459_CR15","first-page":"484","volume":"21","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y., Shen, L. & Peng, Z. Advances in MET tyrosine kinase inhibitors in gastric cancer. Cancer Biol. Med. 21, 484\u2013498 (2024).","journal-title":"Cancer Biol. Med."},{"key":"4459_CR16","doi-asserted-by":"publisher","first-page":"e1691","DOI":"10.1634\/theoncologist.2020-0274","volume":"25","author":"SP Chaudhary","year":"2020","unstructured":"Chaudhary, S. P. et al. Revisiting MET: clinical characteristics and treatment outcomes of patients with locally advanced or metastatic, MET-amplified esophagogastric cancers. Oncologist 25, e1691\u2013e1700 (2020).","journal-title":"Oncologist"},{"key":"4459_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2022.1610697","volume":"28","author":"J Ko","year":"2022","unstructured":"Ko, J. et al. MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer. Pathol. Oncol. Res. 28, 1610697 (2022).","journal-title":"Pathol. Oncol. Res."},{"key":"4459_CR18","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1200\/JCO.2011.35.4928","volume":"29","author":"JK Lennerz","year":"2011","unstructured":"Lennerz, J. K. et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 29, 4803\u20134810 (2011).","journal-title":"J. Clin. Oncol."},{"key":"4459_CR19","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1158\/1078-0432.CCR-18-1337","volume":"25","author":"E Van Cutsem","year":"2019","unstructured":"Van Cutsem, E. et al. A multicenter phase II study of AMG 337 in patients with MET-amplified gastric\/gastroesophageal junction\/esophageal adenocarcinoma and other MET-amplified solid tumors. Clin. Cancer Res. 25, 2414\u20132423 (2019).","journal-title":"Clin. Cancer Res."},{"key":"4459_CR20","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/2159-8290.CD-19-0442","volume":"9","author":"J Lee","year":"2019","unstructured":"Lee, J. et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov. 9, 1388\u20131405 (2019).","journal-title":"Cancer Discov."},{"key":"4459_CR21","unstructured":"HUTCHMED announces enrollment completed of SAFFRON global phase III trial of ORPATHYS\u00ae and TAGRISSO\u00ae combination for certain lung cancer patients with MET overexpression and\/or amplification after progression on TAGRISSO\u00ae. HUTCHMED https:\/\/www.hutch-med.com\/saffron-global-phiii-enrollment-completion (2025)."},{"key":"4459_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(25)01811-2","volume":"407","author":"S Lu","year":"2026","unstructured":"Lu, S. et al. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial. Lancet 407, 375\u2013387 (2026).","journal-title":"Lancet"},{"key":"4459_CR23","unstructured":"HUTCHMED announces china approval for ORPATHYS\u00ae in combination with TAGRISSO\u00ae for the treatment of lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy. HUTCHMED https:\/\/www.hutch-med.com\/china-approval-for-orpathys-plus-tagrisso-for-lung-cancer-with-met-amplification-after-1l-egfr-inhibitor\/ (2025)."},{"key":"4459_CR24","unstructured":"HUTCHMED announces NMPA full approval for ORPATHYS\u00ae (savolitinib) in China for patients with locally advanced or metastatic MET exon 14 NSCLC. HUTCHMED https:\/\/www.hutch-med.com\/nmpa-full-approval-for-orpathys-savolitinib-for-met14-nsclc\/ (2025)."},{"key":"4459_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02841-7","volume":"21","author":"J Li","year":"2023","unstructured":"Li, J. et al. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study. BMC Med. 21, 173 (2023).","journal-title":"BMC Med."},{"key":"4459_CR26","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara, K. et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19, 1437\u20131448 (2018).","journal-title":"Lancet Oncol."},{"key":"4459_CR27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/oncolo\/oyab066","volume":"27","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Phase Ia\/Ib study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, efficacy, and biomarkers. Oncologist 27, 342\u2013e383 (2022).","journal-title":"Oncologist"},{"key":"4459_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11523-021-00811-8","volume":"16","author":"T Aparicio","year":"2021","unstructured":"Aparicio, T. et al. The activity of crizotinib in chemo-refractory MET-amplified esophageal and gastric adenocarcinomas: results from the AcSe-Crizotinib program. Target Oncol. 16, 381\u2013388 (2021).","journal-title":"Target Oncol."},{"key":"4459_CR29","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1158\/1078-0432.CCR-18-1341","volume":"25","author":"DS Hong","year":"2019","unstructured":"Hong, D. S. et al. Phase I study of AMG 337, a highly selective small-molecule MET inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 25, 2403\u20132413 (2019).","journal-title":"Clin. Cancer Res."},{"key":"4459_CR30","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461\u20132471 (2017).","journal-title":"Lancet"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04459-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04459-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04459-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:01:43Z","timestamp":1786629703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04459-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4459"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04459-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S. Fan, P.L., J.Y., M.H., Q.X., L. Wang, Y.R. and S. Fu are employees of HUTCHMED. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}